NUDT1 and cancer: Therefore, we aimed to explore potential differences in the sensitivity of cancer cells exposed to acute and chronic-cycling anoxia/reoxygenation stress (chronic-cycling hypoxia) to the clinically relevant MTH1-inhibitor TH1579 and to test whether a multi-targeting approach combining the glutathione withdrawer piperlongumine (PLN) and TH1579 may be suited to increase cancer cell sensitivity to TH1579 alone and in combination with IR.